RCT: Empagliflozin does not reduce heart failure hospitalization or death post-myocardial infarction

This randomized, placebo-controlled trial assessed empagliflozin in preventing heart failure or death in patients recently hospitalized for acute myocardial infarction. Among 6,522 patients divided evenly into empagliflozin and placebo groups, there was no significant difference in the primary outcome—a composite of heart failure hospitalization or death—after 17.9 months. The empagliflozin group saw 8.2% experiencing the primary outcome versus 9.1% in the placebo group, yielding a non-significant hazard ratio of 0.90 (95% CI, 0.76 to 1.06; P=0.21). The results indicate that empagliflozin does not effectively reduce the risk of heart failure or mortality compared to placebo in this setting.

Reference (link to abstract – $ for full-text):

Butler, J. et al. (2024). Empagliflozin after Acute Myocardial Infarction. N Engl J Med, 390(16), 1455-1466. DOI: 10.1056/NEJMoa2314051